Skip to main content

Table 1 Subject demographic characteristics and severity classifications: development data

From: Using medication utilization information to develop an asthma severity classification model

Variables All asthma, (n = 3593) Classified by Asthma severity, n (%) p-value
Stage 1 (n = 2253, 62.71%) Stage 2 (n = 199, 5.54%) Stage 3 (n = 819, 22.79%) Stage 4 (n = 322, 8.96%)
Gender, n(%)       0.1548
 Female 2101 (58.47) 1285 (57.04) 123 (61.81) 498 (60.81) 195 (60.56)  
 Male 1492 (41.53) 968 (42.96) 76 (38.19) 321 (39.19) 127 (39.44)  
Age, n(%)       <.0001
 18–34 880 (24.49) 511 (22.68) 55 (27.64) 231 (28.21) 83 (25.78)  
 35–44 609 (16.95) 355 (15.76) 46 (23.12) 143 (17.46) 65 (20.19)  
 45–54 660 (18.37) 406 (18.02) 39 (19.60) 148 (18.07) 67 (20.81)  
 55–64 619 (17.23) 405 (17.98) 31 (15.58) 144 (17.58) 39 (12.11)  
65 825 (22.96) 576 (25.57) 28 (14.07) 153 (18.68) 68 (21.12)  
CCI, Mean(SD) 0.39 (0.85) 0.41 (0.85) 0.28 (0.84) 0.34 (0.73) 0.38 (1.05) 0.0435
Obesity, n(%) 10 (0.28) 9 (0.40) 0 (0.00) 1 (0.12) 0 (0.00) 0.6141
Sinusitis, n(%) 40 (1.11) 21 (0.93) 2 (1.01) 15 (1.83) 2 (0.62) 0.1808
GERD, n(%) 11 (0.31) 10 (0.44) 0 (0.00) 0 (0.00) 1 (0.31) 0.2207
Medication utilization, n(%)
 ICS/LABA 866 (24.10) 0 (0.00) 0 (0.00) 660 (80.59) 206 (63.98) <.0001
 ICS 309 (8.60) 0 (0.00) 199 (100.0) 89 (10.87) 21 (6.52) <.0001
 OCS 366 (10.19) 0 (0.00) 0 (0.00) 203 (24.79) 163 (50.62) <.0001
 SABA 822 (22.88) 423 (18.77) 54 (27.14) 267 (32.60) 78 (24.22) <.0001
 SAMA 111 (3.09) 49 (2.17) 5 (2.51) 43 (5.25) 14 (4.35) 0.0001
 SABA/SAMA 155 (4.31) 71 (3.15) 9 (4.52) 56 (6.84) 19 (5.90) <.0001
# of patient having acute exacerbation, n(%) 349(9.71) 184(8.17) 19(9.55) 98(11.97) 48 (14.91) 0.0001
 Hospitalization 52 (1.45) 28 (1.24) 4 (2.01) 9 (1.10) 11 (3.42) 0.0144
 Emergency department visit 160(4.45) 79(3.51) 8(4.02) 54(6.59) 19(5.90) 0.0016
 Short-acting drug 218(6.07) 115(5.10) 9(4.52) 63(7.69) 31(9.63) 0.0015
  1. CCI Charlson Comorbidity Index, GERD Gastroesophageal reflux disease, ICS inhaled corticosteroid, OCS oral corticosteroid, SABA short-acting inhaled β2-agonist, LABA long-acting inhaled β2-agonist, SAMA short-acting muscarinic receptor antagonists